Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million

Reuters

2025/11/06

<a href="https://laohu8.com/S/VMD">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million

Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581707336"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581707336\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581707336?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581707336","market":"us","top_or_hot":-1,"title":"Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VMD\">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VMD\">Viemed Healthcare</a> reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3t00dX:1","article_id":"2581707336","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581707336","pubTimestamp":1762378433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","VMD":"Viemed Healthcare, Inc."},"translate_title":"Viemed Healthcare报告第三季度净收入为7190万美元，净利润为350万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VMD":0.9},"content_text":"Viemed Healthcare reports Q3 net revenue of $71.9 million and net income of $3.5 million\n    \n\n        Viemed Healthcare Inc. reported net revenues of $71.9 million for the quarter ended September 30, 2025, an increase of 24.0% or $13.9 million over the same period in 2024. Net income attributable to Viemed for the quarter was $3.5 million, or $0.09 per diluted share. Adjusted EBITDA reached $16.1 million, up 15.5% compared to the prior year quarter. Net cash provided by operating activities was $18.4 million for the quarter, with free cash flow of $12.4 million. During the period, Viemed completed the acquisition of Lehan's Medical Equipment on July 1, 2025, which was immediately accretive to net income and earnings per share. The company completed its 2025 share repurchase program and updated its adjusted EBITDA guidance for the year to a range of $60.0 million to $62.0 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097432) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}